{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 41,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a 2D grid to map dose combinations against regulatory requirements (Project Optimus).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/20",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.72,
        "w": 0.38,
        "x": 0.25,
        "y": 0.16
      },
      "kind": "chart",
      "text": "Dose combination grid",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd3bbb67-b43b-4688-8930-3694680f7a40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "* As part of the naporafenib + trametinib combination. BID: twice a day; QD: once a day",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d4eb865-438a-49fd-be65-48d0056749bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.66,
        "y": 0.6
      },
      "kind": "legend",
      "text": "SEACRAFT-1 dose (purple) and SEACRAFT-2 dose (blue)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33604368-e504-476d-97ea-94264640e2a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.32,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Data from SEACRAFT-1 and SEACRAFT-2 complement each other, allowing us to efficiently test the full effective dose range of naporafenib + trametinib within the two trials to optimize the benefit/risk profile in both indications of interest",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4905158c-a023-4490-905c-ae0c178e007a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Dose optimization designed to enhance combination benefit/risk profile to increase probability of regulatory success in light of Project Optimus",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9742a745-fc53-4788-ab37-1f3fe642f2fc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "de23d9a1-dee7-48e0-8aeb-03db963fbbe5",
      "evidence": "Dose combination grid",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "matrix-2x2",
      "slug": null,
      "matchId": "2ffd6d0d-daf2-4720-b95a-fc52fa6374ea",
      "evidence": "The chart maps two variables (naporafenib dose vs trametinib dose) to show optimization space.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
      "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
      "position": 1,
      "objective": "What are the potential benefits of investing in Erasca's pipeline?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}